Trastuzumab Emtansine (Genetical Recombination) for Intravenous Infusion 100mg (Kadcyla® / カドサイラ点滴静注用100mg)

JPY ¥294,800

Japanese Anti-HER2 Antibody-Drug Conjugate (Trastuzumab Emtansine 100mg). For intravenous infusion in HER2-positive unresectable/recurrent breast cancer and adjuvant treatment of HER2-positive breast cancer. 1 vial. Mfd. by Chugai Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥271,216
10 - 19 12% JPY ¥259,424
20 + 18% JPY ¥241,736
SKU: KDC-100-INJ Category:

Description

Product Overview / 商品概要

Kadcyla for Intravenous Infusion 100mg (カドサイラ点滴静注用100mg)
Generic: Trastuzumab Emtansine (Genetical Recombination) / トラスツズマブ エムタンシン(遺伝子組換え)
Therapeutic Category: Anti-HER2 Antibody-Drug Conjugate (Tubulin Polymerization Inhibitor) / 抗HER2抗体チューブリン重合阻害剤複合体
Manufactured by: Chugai Pharmaceutical Co., Ltd. / 中外製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Trastuzumab Emtansine (Genetical Recombination) 106mg per vial (overfill; delivers 100mg upon reconstitution at 20mg/mL with 5.0mL water for injection) / 1バイアル中 トラスツズマブ エムタンシン(遺伝子組換え)106mg(過量充填)
Additives: Purified sucrose 318mg, Succinic acid 6.3mg, Sodium hydroxide 2.4mg, Polysorbate 20 1.1mg / 精製白糖 318mg、コハク酸 6.3mg、水酸化ナトリウム 2.4mg、ポリソルベート20 1.1mg
Appearance: White lyophilized cake (vial). After reconstitution with 5.0mL water for injection: clear to opalescent, colorless to slightly brownish solution; pH 4.7–5.3; osmolality 157–261 mOsm/kg
外観: 白色の塊(バイアル)。注射用水5.0mLに溶解後:澄明~乳白光を呈する、無色~微褐色の液、pH 4.7~5.3、浸透圧 157~261mOsm/kg

Indications / 効能効果

EN: ○Unresectable or recurrent HER2-positive breast cancer
○Adjuvant drug therapy for HER2-positive breast cancer
JA: ○HER2陽性の手術不能又は再発乳癌
○HER2陽性の乳癌における術後薬物療法

Dosage and Administration / 用法用量

EN: Usually, administer trastuzumab emtansine (genetical recombination) at 3.6mg/kg body weight by intravenous infusion every 3 weeks. For adjuvant therapy, the number of administrations is limited to a maximum of 14 cycles.
JA: 通常、成人にはトラスツズマブ エムタンシン(遺伝子組換え)として1回3.6mg/kg(体重)を3週間間隔で点滴静注する。ただし、術後薬物療法の場合には、投与回数は14回までとする。

Contraindications / 禁忌

EN: 2.1 Patients with a history of hypersensitivity to any component of this product or trastuzumab (genetical recombination), including serious infusion reactions that are difficult to differentiate from hypersensitivity and may lead to death.
2.2 Pregnant women or women who may be pregnant.
JA: 2.1 本剤の成分又はトラスツズマブ(遺伝子組換え)に対し過敏症(過敏症と鑑別困難で死亡につながるおそれのある重篤なInfusion reactionを含む)の既往歴のある患者
2.2 妊婦又は妊娠している可能性のある女性

Regulatory Information / 規制情報

Approval No.: 22500AMX01816
Sales Started: April 2014 / 2014年4月
Classification Code: 874291
Storage: Store at 2–8°C (refrigerated) / 2~8℃保存
Shelf Life: 48 months / 48箇月

Packaging / 包装

Main Package (for sale): 1 vial / 1バイアル
Other Available Packages (by special order): 1 vial

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Trastuzumab Emtansine (Genetical Recombination) for Intravenous Infusion 100mg (Kadcyla® / カドサイラ点滴静注用100mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Trastuzumab Emtansine (Genetical Recombination) for Intravenous Infusion 100mg (Kadcyla®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.